Document is current

Article History

Received: 19 February 2026

Accepted: 17 May 2026

First Online: 27 May 2026

Declarations

:

: CT serves as Editor of the Primary Section of Annals of Medicine, and member of the Editorial Board of The Journal of Headache and Pain. BR has served on advisory boards for, consulted for, and/or been a speaker for Allergan/AbbVie, Eli Lilly, Novartis, Organon, Perfood, and Teva. She has received research funding from Lundbeck, Novartis, German Migraine and Headache Society, German Research Foundation, and Else Kröner-Fresenius-Stiftung. She is an associate editor of The Journal of Headache and Pain and Cephalalgia. RO reports personal fees from AbbVie, Bayer, Eli Lilly, Lundbeck, Novartis, Organon, Pfizer, and Teva; he is Associate Editor for Arquivos de Neuropsiquiatria and Editorial Board Member for The Journal of Headache and Pain, International Journal of Stroke, and Confinia Cephalalgica. RM reports receiving personal fees from AbbVie, Biomedia, Eli Lilly, Lundbeck, Organon, Pfizer, and Teva, and grants from the Italian Ministry of Health, outside of the submitted work. WWG has no conflicts of interest to report. PM is the Editor in Chief of the Journal of Headache and pain and of SN Comprehensive Clinical Medicine. LM has no conflict of interest to declare.

: Not applicable.

: Not applicable.